Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Regulatory News (OVB)

  • There is currently no data for OVB

Interim Results

30 Sep 2013 07:00

RNS Number : 1665P
Ovoca Gold PLC
30 September 2013
Β 

Ovoca Gold plc ("Ovoca" or the "Company")

2013 Interim Results

Β 

Ovoca Gold is pleased to announce its interim financial statements and report covering the six month period from 1 January 2013 to 30 June 2013.

Β 

Highlights:

Β 

Β· Cash and cash equivalents and available for sale financial assets of US$31.3 million as at 30 June 2013;

Β· Total comprehensive loss for the period of US$18.2 million as at 30 June 2013 with the Company negatively impacted by adverse movements in its holdings of available for sale financial assets, driven by the fall in gold prices during the period;

Β· Completion of the disposal of the Olcha gold-silver deposit to Polymetal International plc ("Polymetal") in January 2013 for a consideration of 775,000 shares in Polymetal;

Β· Total dividends received amounting to US$753,000 relating to our holding of Polymetal shares; and

Β· Mapping and reconnaissance works continued on Stakhanovsky in preparation for the further development of the project.

Β 

Β 

Post period:

Β 

Β· Feasibility study and Resource Calculation study on our Stakhanovsky project (prepared in accordance with Russian Standards) submitted to the State Committee of Reserves for review and approval; and

Β· Conservation works completed both on Stakhanovsky and Rassoshinskaya sites in preparation for the winter season.

Β 

Β 

CEO's Letter

Β 

Dear shareholders,

Β 

It is my pleasure to report to you our financials and the results of our work for the first half of 2013. The first six months of this year proved to be a very challenging period not only for our Company, but for the whole mining sector. The fall in commodity prices during the period had a significant impact on the gold mining industry. We were also affected by this retreat in gold prices and recognised unrealized losses from the securities which we hold in treasury.

Β 

Despite that negative impact, our financial position remains strong. We duly managed our cash position and received US$544,000 from deposits, received US$753,000 in dividends through our holding of Polymetal shares and also reduced our operational expenses. Our holding of Polymetal shares increased up to a total of 1,405,000 shares due to the successful completion of the disposal of the Olcha deposit in January when we received a consideration of 775,000 Polymetal shares for the project. After taking into account the unstable market conditions during the period, we decided to focus our attention on completion of technological and analytical studies of our Stakhanovsky asset and on the preparation of feasibility and resource calculation studies (in accordance with Russian standards). These studies were completed and submitted to the State Committee of Reserves and are being reviewed now. A JORC compliant resource update report for Stakhanovsky is nearing completion and will be announced in the coming weeks. Finally, mining equipment on both of our sites has been stored, conserved and prepared for the forthcoming winter period.

Β 

Β 

Sincerely,

Kirill Golovanov

CEO

Β 

The financial results for the half year ended 30 June 2013 can be viewed at the following link:

http://www.rns-pdf.londonstockexchange.com/rns/1665P_-2013-9-27.pdf

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IR EASNXADDDEFF
Date   Source Headline
29th Jul 20227:00 amRNSCompletion of Enrollment in Phase II Study
30th Jun 20227:00 amRNSAnnual Financial Report
7th Mar 20229:00 amRNSStatement re Russian Business Operations
23rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
22nd Feb 20223:30 pmRNSRussian Marketing Authorisation for Orenetide
31st Jan 20227:00 amRNSBoard Changes and Update
30th Dec 20217:00 amRNSDirectorate Change
4th Nov 20213:53 pmRNSHolding(s) in Company
4th Nov 20213:50 pmRNSDirector/PDMR Shareholding
4th Nov 20213:46 pmRNSBoard Change
14th Sep 20217:00 amRNSInterim Results
29th Jul 20215:00 pmRNSResult of AGM
24th Jun 20217:00 amRNSAnnual Report and Notice of AGM
10th Mar 20217:00 amRNSMigration of Participating Securities
16th Feb 20212:00 pmRNSResult of EGM
29th Jan 20217:00 amRNSFirst Patient Enrolled in Phase II Study - BP-101
25th Jan 20213:30 pmRNSNotice of EGM
5th Jan 20217:00 amRNSRe-Filing of Marketing Authorisation Application
17th Dec 20202:45 pmRNSResult of AGM
27th Nov 20203:08 pmRNSNotice of AGM
9th Oct 20207:00 amRNSAppointment of Chief Business Officer
2nd Oct 202011:06 amRNSSecond Price Monitoring Extn
2nd Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 20209:05 amRNSSecond Price Monitoring Extn
2nd Oct 20209:00 amRNSPrice Monitoring Extension
2nd Oct 20207:00 amRNSUpdate re Russian Marketing Authorisation
28th Sep 20207:00 amRNSDeath of a Director
21st Sep 20207:00 amRNSInterim Results
14th Aug 202011:05 amRNSSecond Price Monitoring Extn
14th Aug 202011:00 amRNSPrice Monitoring Extension
26th Jun 20207:00 amRNSAnnual Report
14th Apr 20202:05 pmRNSSecond Price Monitoring Extn
14th Apr 20202:00 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSAcquisition of Remaining Minority Interest in IVIX
7th Nov 201912:45 pmRNSAttendance at Bio-Europe Conference
16th Sep 20197:00 amRNSInterim Results
12th Sep 20197:00 amRNSFiling of Marketing Authorisation Application
28th Aug 20197:00 amRNSDirectorate Change
8th Aug 20194:14 pmRNSResult of AGM
8th Aug 20199:05 amRNSSecond Price Monitoring Extn
8th Aug 20199:00 amRNSPrice Monitoring Extension
8th Aug 20197:00 amRNSAGM Statement
26th Jul 20197:00 amRNSDirectorate Change
25th Jul 20194:41 pmRNSSecond Price Monitoring Extn
25th Jul 20194:35 pmRNSPrice Monitoring Extension
28th Jun 20197:00 amRNSAnnual Report and Notice of AGM
23rd Apr 20197:00 amRNSUS and EU Clinical Development Plans
29th Mar 20197:00 amRNSDirector/PDMR Shareholding
27th Mar 20197:00 amRNSOperational Update & Additional Investment in IVIX

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.